Members in Pennsylvania, West Virginia, New York, and Delaware all saw weight management coverage removed from standard plans
At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
In the published Phase 2 research (Jastreboff et al., NEJM 2023), Retatrutide produced the largest body-weight outcomes of any single-compound incretin programme reported to date, distinguishing the triple-agonist class from dual agonists like Tirzepatide and single-target agonists like Semaglutide
Insulin Resistance and Diabetes
World Obes Fed